Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

MYOZYME® (ALGLUCOSIDASE ALFA) 50MG POWDER FOR SOLUTION FOR INFUSION [SIN13543P]

Active ingredients: ALGLUCOSIDASE ALFA

View product's general information
Last updated on 9 October 2026

Product Info

MYOZYME® (ALGLUCOSIDASE ALFA) 50MG POWDER FOR SOLUTION FOR INFUSION

[SIN13543P]

Product information

Active Ingredient and Strength

ALGLUCOSIDASE ALFA - 50 MG/VIAL

Dosage Form

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Manufacturer and Country

GENZYME IRELAND LIMITED - IRELAND

Registration Number

SIN13543P

Licence Holder

SANOFI-AVENTIS SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

A16AB07

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

Therapeutic indications
Myozyme is indicated for long-term enzyme replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid α-glucosidase deficiency).
Myozyme is indicated in adults and paediatric patients of all ages.

Dosing

Posology and method of administration
Myozyme treatment should be supervised by a physician experienced in the management of patients with Pompe disease or other inherited metabolic or neuromuscular diseases.
Posology
The recommended dose regimen of alglucosidase alfa is 20 mg/kg body weight administered once every 2 weeks.
Patient response to treatment should be routinely evaluated based on a comprehensive evaluation of all clinical manifestations of the disease.
Paediatric and older people
There is no evidence for special considerations when Myozyme is administered to paediatric patients of all ages or older people.
Patients with renal and hepatic impairment
The safety and efficacy of Myozyme in patients with renal or hepatic impairment have not been evaluated and no specific dose regimen can be recommended for these patients.

Method of administration
Myozyme should be administered as an intravenous infusion.
Infusions should be administered incrementally. It is recommended that the infusion begin at an initial rate of 1 mg/kg/h and be gradually increased by 2 mg/kg/h every 30 minutes if there are no signs of infusion associated reactions (IARs) until a maximum rate of 7 mg/kg/h is reached. IARs are described in section Undesirable effects – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
For instructions on reconstitution and dilution of the medicinal product before administration, see section Special precautions for disposal and other handling – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Contraindications

Contraindications
Life threatening hypersensitivity (anaphylactic reaction) to the active substance or to any of the excipients, when rechallenge was unsuccessful (see sections Special warnings and precautions for use and Undesirable effects – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).